Published in Nature Structural & Molecular Biology
Researchers led by Dr. Xavier Salvatella at IRB Barcelona, with partners at the Max Planck Institute for Molecular Genetics and BC Cancer, have unveiled a novel strategy for targeting the androgen receptor, a key factor in aggressive prostate cancer. They have discovered that exploiting the receptor's propensity to form biomolecular condensates offers a new way to inhibit its activity, potentially revolutionising treatment approaches.
This groundbreaking research has led to the founding of Nuage Therapeutics, which seeks to develop therapies against diseases by targeting proteins that undergo biomolecular condensation. Published in Nature Structural & Molecular Biology, this study opens up exciting possibilities for treating conditions currently deemed challenging.
For more information:
https://www.irbbarcelona.org/en/news/scientific/hard-drug-protein-droplets-reveal-new-ways-inhibit-transcription-factors-aggressive
